全球核酸治疗市场

到 2030 年，全球核酸疗法市场规模将达到 126 亿美元

全球核酸疗法市场规模预计在2024年为54亿美元，预计到2030年将达到126亿美元，2024年至2030年的复合年增长率为15.1%。 RNARNA干扰/短干扰RNA是本报告分析的细分市场之一，预计其复合年增长率为16.3%，到分析期结束时将达到85亿美元。反义寡核苷酸细分市场在分析期间的复合年增长率估计为13.3%。

美国市场规模估计为 15 亿美元，而中国市场预计复合年增长率为 20.2%

美国核酸疗法市场规模预计在2024年达到15亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到28亿美元，在2024-2030年的分析期间内，复合年增长率为20.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为11.0%和13.6%。在欧洲，预计德国市场的复合年增长率约为12.0%。

全球核酸治疗市场－主要趋势与驱动因素摘要

核酸疗法如何重新定义疾病治疗的未来？

核酸疗法正在再形成现代医学，因为它能够精准操控基因表现和细胞功能。这些治疗方法在转录或翻译层面的早期阶段微型RNA，从而能够以极高的特异性纠正基因功能障碍。

这种创新方法为治疗先前「无法治癒」的靶点（例如非编码RNA、基因融合和罕见单基因疾病）铺平了道路。 nusinersen（用于治疗脊髓性肌肉萎缩症）和patisiran（用于治疗遗传性转甲状腺素蛋白介导的类淀粉沉积症样变性）等药物已检验了抗反义寡核苷酸（ASO）和siRNA的临床效用。同时，因新冠疫苗而引起全球关注的mRNA技术，如今正被重新用于肿瘤学、自体免疫疾病、个人化疫苗等领域。这一转变标誌着从广泛的干预措施向高度个人化的基因级医学的转变。

哪些技术进步支持临床采用和交付？

核酸疗法的成功取决于能够保护这些脆弱分子并实现细胞特异性摄取的递送技术。脂质奈米颗粒 (LNP) 已成为最具可扩展性和临床检验的载体，特别适用于 mRNA 和 siRNA 疗法。这些 LNP 可以保护治疗有效载荷免于降解，促进其透过内吞作用进入细胞，并触发细胞质内的受控释放。可电离脂质设计、聚乙二醇化策略和标靶配体的改进显着提高了 LNP 系统的功效和安全性。

除了LNP之外，基于聚合物的奈米颗粒、树状聚合物、外泌体以及基于GalNAc的偶联递送技术（用于肝臟靶向）正在拓展给药途径和目标组织的范围。例如，GalNAc偶联的siRNA可用于每月一次的皮下给药，用于治疗慢性肝病。此外，电穿孔、病毒载体（AAV、慢病毒）和新型水凝胶正在肿瘤学和中枢神经系统疾病中用于局部或组织选择性递送的测试中。生物资讯工具目前在优化序列设计以避免脱靶效应和增强细胞内稳定性方面发挥关键作用。

同时，合成化学的进展正在改善寡核苷酸序列的稳定性、亲和性和免疫抗原性原性。骨架修饰（例如硫代磷酸酯）、糖环变异（2'-O-甲基、2'-氟）和锁核酸 (LNA) 结构改善了药物动力学，并最大限度地降低了免疫活化。这些进展使得给药频率更高、循环半衰期更长、毒性更低，这些都是扩大临床应用和获得监管核准的重要因素。

哪些治疗领域和公司正在推动市场渗透？

罕见遗传疾病、肿瘤和感染疾病是核酸疗法应用的前沿领域。在传统小分子化合物通常无效的罕见疾病中，抗反义寡核苷酸（ASO）和siRNA透过修復或定序缺陷基因产物展现出显着的疗效。Duchenne氏肌肉失养症、肌萎缩侧索硬化症（ALS）和巴滕症等疾病是目前临床研究的重点目标。美国和欧洲的孤儿药资格认定和加速核准程序，使该领域的研发者能够更快地将药物推向市场。

核酸疗法正被用于基因静默、新抗原疫苗开发和免疫细胞重编程。与Moderna和Merck等製药巨头合作开发的个人化mRNA癌症疫苗正在进入黑色素瘤和肺癌的后期临床试验阶段。同时， RNA干扰平台正被客製化以抑制KRAS和STAT3等促进要素。虽然药物传递仍然是固体癌治疗的一大障碍，但肿瘤内和局部发行策略正在改善药物的分布和疗效。

Ionis Pharmaceuticals、Alnylam、Moderna、BioNTech 和 Sarepta Therapeutics 等领先公司正利用其在寡核苷酸化学和递送方面的深厚专业知识引领行业发展。新兴生物技术公司也在核酸疗法和人工智慧主导的药物设计的交叉领域进行创新。中国和韩国等市场参与企业正在透过政策支持和智慧财产权协调加速其在本国的发展，从而提升了区域在全球治疗产品线的参与。

是什么推动了全球核酸治疗市场的成长？

全球核酸治疗市场的成长受到多种因素的推动，包括人们对遗传疾病认知的不断提高、疫苗平台的快速发展以及对精准医疗日益增长的需求。对人类基因组学和转录组学理解的不断加深促进了疾病标靶和生物标记的识别，扩大了可透过核酸干预治疗的适应症范围。

临床成功减少了相关人员的疑虑，并加速了从临床前阶段到临床阶段的投资。策略合作伙伴关係、授权协议和创业投资资金筹措涌入专注于RNA的新兴企业和交付技术平台。 COVID-19 mRNA疫苗的成功已成为全球检验事件，促使医疗保健系统和监管机构优先考虑可扩展、快速的核酸疗法，以应对未来的流行病、癌症和新兴疾病。

此外，监管机构正在为这些治疗方法制定更清晰的途径和快速审查程序，特别是针对那些危及生命且未满足医疗需求的疾病。基于疗效的定价和基于价值的合约支援的报销模式也在不断发展，以应对个人化核酸疗法的高成本。製造能力的提升、药物设计的数位化以及治疗方法的多样化，正在将核酸疗法从利基生物技术应用转变为21世纪医学的基础支柱。

部分

产品（RNA干扰、短干扰RNA、反义寡核苷酸、其他产品）、应用（自体免疫疾病、感染疾病、遗传疾病、癌症、其他应用）、最终用户（医院/诊所最终用户、学术/研究机构最终用户）

受访公司范例

• Alnylam Pharmaceuticals
• Anima Biotech
• Arrowhead Pharmaceuticals
• BioNTech SE
• BridgeBio Pharma
• CureVac NV
• Dicerna Pharmaceuticals
• Dynavax Technologies
• Gilead Sciences Inc.
• Ionis Pharmaceuticals
• Moderna Inc.
• NOXXON Pharma NV
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Phio Pharmaceuticals Corp.
• Precision BioSciences
• ProQR Therapeutics NV
• Sarepta Therapeutics
• Silence Therapeutics
• Wave Life Sciences

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 比赛

Global Nucleic Acid Based Therapeutics Market to Reach US$12.6 Billion by 2030

The global market for Nucleic Acid Based Therapeutics estimated at US$5.4 Billion in the year 2024, is expected to reach US$12.6 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2024-2030. RNA Interference & Short Interfering RNAs, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$8.5 Billion by the end of the analysis period. Growth in the Antisense Oligonucleotides segment is estimated at 13.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 20.2% CAGR

The Nucleic Acid Based Therapeutics market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 20.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.0% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.0% CAGR.

Global Nucleic Acid Based Therapeutics Market - Key Trends & Drivers Summarized

How Are Nucleic Acid Therapeutics Redefining the Future of Disease Treatment?

Nucleic acid based therapeutics are reshaping modern medicine by enabling precise manipulation of gene expression and cellular function. These therapies, which include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), aptamers, and messenger RNAs (mRNAs), offer targeted intervention at the genetic level, bypassing conventional protein-focused approaches. Unlike traditional drugs that modulate protein pathways post-translation, nucleic acid therapeutics intervene earlier-at the transcription or translation stage-enabling profound specificity in correcting genetic dysfunctions.

This transformative approach has opened doors to treating previously “undruggable” targets such as non-coding RNAs, gene fusions, and rare monogenic diseases. Therapies like nusinersen (for spinal muscular atrophy) and patisiran (for hereditary transthyretin-mediated amyloidosis) have validated the clinical viability of ASOs and siRNAs. Meanwhile, mRNA technologies-propelled to global attention by COVID-19 vaccines-are now being repurposed for oncology, autoimmune conditions, and personalized vaccines. This shift marks a transition from broad-spectrum interventions to highly individualized, gene-level medicine.

What Technological Advances Are Supporting Clinical Translation and Delivery?

The success of nucleic acid therapies hinges on delivery technologies that protect these fragile molecules and enable cell-specific uptake. Lipid nanoparticles (LNPs) have emerged as the most scalable and clinically validated carriers, particularly for mRNA and siRNA drugs. These LNPs shield therapeutic payloads from degradation, facilitate cellular entry via endocytosis, and trigger controlled release in the cytosol. Improvements in ionizable lipid design, PEGylation strategies, and targeting ligands have significantly boosted the efficacy and safety of LNP systems.

Beyond LNPs, polymer-based nanoparticles, dendrimers, exosomes, and conjugated delivery using GalNAc (for liver targeting) are expanding the range of administration routes and target tissues. For example, GalNAc-conjugated siRNAs have enabled subcutaneous administration for chronic liver conditions with monthly dosing schedules. Additionally, electroporation, viral vectors (AAV, lentivirus), and novel hydrogels are being tested for localized or tissue-selective delivery in oncology and CNS disorders. Bioinformatics tools now play a pivotal role in optimizing sequence design to avoid off-target effects and enhance intracellular stability.

Simultaneously, synthetic chemistry advancements are enhancing the stability, affinity, and immunogenicity profiles of oligonucleotide sequences. Backbone modifications (e.g., phosphorothioate), sugar ring alterations (2’-O-methyl, 2’-fluoro), and locked nucleic acid (LNA) architectures have improved pharmacokinetics and minimized immune activation. These advancements are enabling more frequent dosing, longer circulation half-lives, and reduced toxicity profiles-critical factors in expanding clinical adoption and regulatory acceptance.

Which Therapeutic Areas and Companies Are Driving Market Penetration?

Rare genetic diseases, oncology, and infectious diseases are at the forefront of nucleic acid therapeutic adoption. In rare diseases, where traditional small molecules often fall short, ASOs and siRNAs have demonstrated remarkable efficacy by restoring or silencing faulty gene products. Disorders such as Duchenne muscular dystrophy, amyotrophic lateral sclerosis (ALS), and Batten disease are among the key targets under active clinical investigation. The orphan drug designation and accelerated approval pathways in the U.S. and Europe are enabling faster market entry for developers in this segment.

Oncology represents a fast-emerging application area, with nucleic acid therapeutics being employed in gene silencing, neoantigen vaccine development, and immune cell reprogramming. Personalized mRNA cancer vaccines, developed in collaboration between pharma giants like Moderna and Merck, are advancing into late-stage trials for melanoma and lung cancer. Simultaneously, RNA interference platforms are being tailored to silence tumor drivers such as KRAS and STAT3. Delivery challenges in solid tumors remain a hurdle, but intratumoral and local delivery strategies are improving drug distribution and efficacy.

Leading players such as Ionis Pharmaceuticals, Alnylam, Moderna, BioNTech, and Sarepta Therapeutics dominate the landscape, leveraging deep expertise in oligonucleotide chemistry and delivery. Emerging biotechs are also innovating at the intersection of nucleic acid therapy and AI-driven drug design. Markets such as China and South Korea are accelerating homegrown development through policy support and IP harmonization, increasing regional participation in the global therapeutic pipeline.

What Is Fueling Growth in the Global Nucleic Acid Based Therapeutics Market?

The growth in the global nucleic acid based therapeutics market is driven by several factors, including rising genetic disease awareness, rapid vaccine platform development, and the growing demand for precision medicine. Increased understanding of human genomics and transcriptomics has enabled better identification of disease targets and biomarkers, expanding the pool of treatable indications through nucleic acid interventions.

Clinical success stories have reduced stakeholder skepticism and accelerated investments across preclinical and clinical stages. Strategic collaborations, licensing deals, and venture capital funding are flowing into RNA-focused startups and delivery technology platforms. The success of COVID-19 mRNA vaccines served as a global validation event, prompting healthcare systems and regulators to prioritize scalable and rapid-response nucleic acid therapies for future pandemics, cancer, and emerging diseases.

Moreover, regulatory agencies have established clearer pathways and expedited review programs for these therapies, especially when targeting life-threatening conditions with high unmet needs. Reimbursement models are evolving to accommodate the high costs of personalized nucleic acid therapies, supported by outcome-based pricing and value-based contracting. With expanding manufacturing capacity, digital drug design, and increasing therapeutic diversity, nucleic acid based therapeutics are transitioning from niche biotech applications to a foundational pillar of 21st-century medicine.

SCOPE OF STUDY:

The report analyzes the Nucleic Acid Based Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides, Other Products); Application (Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application, Other Applications) End-User (Hospitals & Clinics End-User, Academic & Research Institutes End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Alnylam Pharmaceuticals
• Anima Biotech
• Arrowhead Pharmaceuticals
• BioNTech SE
• BridgeBio Pharma
• CureVac N.V.
• Dicerna Pharmaceuticals
• Dynavax Technologies
• Gilead Sciences Inc.
• Ionis Pharmaceuticals
• Moderna Inc.
• NOXXON Pharma N.V.
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Phio Pharmaceuticals Corp.
• Precision BioSciences
• ProQR Therapeutics N.V.
• Sarepta Therapeutics
• Silence Therapeutics
• Wave Life Sciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Nucleic Acid Based Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Genetic and Rare Disease Research Throws the Spotlight on Nucleic Acid Based Therapeutics
  • Rapid Advancement in mRNA Technology Drives Breakthroughs Beyond Vaccines
  • Expansion of CRISPR and RNAi Platforms Strengthens Business Case for Nucleic Acid-Based Interventions
  • Development of Stabilized Oligonucleotides Enhances Therapeutic Efficacy and Shelf Life
  • Partnerships Between Biotech Startups and Pharma Giants Propel Pipeline Expansion
  • Regulatory Flexibility for Orphan and Breakthrough Therapies Accelerates Clinical Advancements
  • Integration of Targeted Delivery Systems Boosts Precision and Minimizes Off-Target Effects
  • Rise in Next-Generation Sequencing Capabilities Enhances Target Identification and Customization
  • Government Funding for Rare and Genetic Disorders Drives Market Entry for Nucleic Acid Therapies
  • Growing Role of AI in RNA Structure Prediction Accelerates Discovery and Development Cycles
  • Advances in Non-Viral Delivery Mechanisms Open New Pathways for Nucleic Acid-Based Drug Platforms
  • Embrace of Modular Chemistry Accelerates Scalable Production of Oligo-Based Therapeutics
  • Positive Clinical Data for Antisense and siRNA Candidates Spurs Investor Confidence
  • Emergence of Self-Amplifying RNA and Circular RNA Expands Therapeutic Potential
  • Global Demand for Pandemic-Responsive Drug Platforms Sustains Investment in RNA Toolkits
  • Rising Patient Advocacy for Genetic Cure Options Propels Demand for Novel Therapeutic Modalities
  • Integration of Companion Diagnostics Enhances Clinical and Commercial Success
  • Market Entry of CDMO Players With RNA Expertise Fuels End-to-End Development Pipelines
  • Pursuit of Multi-Target and Multi-Pathway Therapies Expands Use Cases for Nucleic Acid Drugs
  • Growing Use in Oncology, CNS, and Infectious Disease Broadens Market Penetration
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Nucleic Acid Based Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for RNA Interference & Short Interfering RNAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for RNA Interference & Short Interfering RNAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for RNA Interference & Short Interfering RNAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antisense Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antisense Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Antisense Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Genetic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Genetic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Genetic Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• JAPAN
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• CHINA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 47: China Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 50: China Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• EUROPE
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• FRANCE
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 62: France Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 65: France Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• GERMANY
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 80: UK Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 83: UK Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• INDIA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 119: India Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 122: India Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: India 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
• AFRICA
  • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION